Efficacy and Safety of Ustekinumab in Patients with Active Systemic Lupus Erythematosus: Results Through 2 Years of an Open-Label Extension in a Phase 2 Study

CONCLUSION: In the 46 patients who entered the voluntary extension of this phase 2 study, clinical benefit in global and organ-specific SLE-activity measures was observed with ustekinumab through 2years with no new or unexpected safety findings. clinicaltrials.gov: NCT02349061.PMID:34853089 | DOI:10.3899/jrheum.210805

Source: J Rheumatol - December 2, 2021 Category: Rheumatology Authors: Ronald F van Vollenhoven Bevra H Hahn George C Tsokos Peter Lipsky Robert M Gordon Kaiyin Fei Kim Hung Lo Marc Chevrier Shawn Rose Pamela Berry Zhenling Yao Chetan S Karyekar Qing Zuraw Source Type: research